A Phase 1 study led by Dr. Anthony Back at the University of Washington found that a second psilocybin-assisted therapy session significantly improved anxiety, depression, and psychological well-being in metastatic cancer patients, with effects lasting up to 24 weeks. The study, using Filament's botanical psilocybin drug candidate PEX010, showed 69% of participants fell below clinical thresholds for anxiety and depression after the second treatment, with no serious adverse events reported. This supports a shift toward repeatable, protocol-driven psychedelic treatments and aligns with growing U.S. regulatory support for psychedelic research. Filament's PEX010 is now supplied to over 70 clinical sites globally, advancing trials in depression, PTSD, and cancer-related distress.
